Literature DB >> 1889486

Changes in serum erythropoietin levels during allogeneic bone marrow transplantation.

R J Grace1, R G Kendall, C Chapman, A E Hartley, D L Barnard, D R Norfolk.   

Abstract

Serial serum erythropoietin levels were measured in 10 consecutive patients undergoing allogeneic bone marrow transplantation. Observed erythropoietin levels are compared with those predicted from a large control population of anaemic patients not receiving chemotherapy. There was an initial acute rise in serum erythropoietin, peaking between days 1 and 4 after marrow transfusion, which was unrelated to changes in haemoglobin concentration. Patients maintained serum erythropoietin concentrations at around twice the predicted level for the first 2 weeks following transplantation, with a gradual fall into the expected range by wk 3. Erythropoietin levels did not change with episodes of bacterial infection or acute graft-versus-host disease. A patient with severe aplastic anaemia had initial successful engraftment with normalisation of erythropoietin levels, but showed a marked and amplified rise in erythropoietin 2 wk before falling peripheral blood counts indicated failure of the bone marrow graft.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889486     DOI: 10.1111/j.1600-0609.1991.tb00126.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination.

Authors:  P Veng-Pedersen; J A Widness; J Wang; R L Schmidt
Journal:  J Pharmacokinet Biopharm       Date:  1997-10

Review 2.  Inadequate erythropoietin response to anemia: definition and clinical relevance.

Authors:  G Barosi
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

3.  Change in erythropoietin pharmacokinetics following hematopoietic transplantation.

Authors:  J A Widness; R L Schmidt; R J Hohl; F D Goldman; N H Al-Huniti; K J Freise; P Veng-Pedersen
Journal:  Clin Pharmacol Ther       Date:  2007-04-11       Impact factor: 6.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.